SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Regulatory & Safety

Read more breaking news

 

 
News in brief

EMA calls for submission of Type-1 MA variations before end of November

30-Oct-2012
Last updated on 26-Mar-2014 at 13:51 GMT

Pharmaceutical firms should let the EMA know about minor variations to marketing authorisation (MA) by the end of next month if they want to avoid delays over the festive period.

The European Medicines Agency (EMA) issued the warning earlier today, advising authorisation holders to submit any quality type-IA and type-IAin variations for 2012 by Friday 30 November and reminding them that its offices will be closed from December 24 to January 2.

Type-I variations are minor changes that have no impact on the quality, safety or efficacy of the medicine. Marketing-authorisation holders can implement changes of this type before validation by the Agency.

In contrast, type-IB variations can only be implemented once the EMA has accepted the variation or after 30 days following acknowledgment of receipt of a valid application.

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions